Gemcitabine: adverse event reports filed with FDA

33,198

reports as suspect product

0.2% of all reports · about 1,476 a year

2,920

reports, 12 months to June 2026

2,900 in the 12 months before

97.9%

marked serious by the reporter

92.2% across the class

18.3%

record death among outcomes, as reported

6,065 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Gemcitabine reports recording the termmedian drug in nucleoside metabolic inhibitor

1. Disease progressionthe disease advanced12.6%4,174
2. Thrombocytopenialow platelets8.2%2,734
3. Neutropenialow neutrophils, a type of white blood cell7.2%2,387
4. Drug ineffectivethe medicine did not work as expected7%2,339
5. Off label useused for a purpose or in a way not on the label6.8%2,255
6. Anaemialow red blood cells6.4%2,140
7. Malignant neoplasm progression5.3%1,748
8. Nauseafeeling sick4.9%1,633
9. Pyrexiafever4.9%1,630
10. Fatiguetiredness4.1%1,354
11. Vomitingbeing sick4%1,336
12. Diarrhoealoose or frequent stools4%1,314
13. Febrile neutropeniafever with low white blood cells3.6%1,202
14. Deaththe patient died; cause not stated by this term3.3%1,109
15. Pneumonialung infection2.7%910
16. Dyspnoeashortness of breath2.7%908
17. Pancytopenialow counts of all blood cells2.7%907
18. Astheniaweakness or lack of energy2.6%863
19. Leukopenialow white blood cells2.5%846
20. Product use in unapproved indicationused for a purpose not on the label2.4%786
21. Sepsisa severe body-wide response to infection2.3%771
22. Neuropathy peripheralnerve damage in hands or feet2.3%766
23. Abdominal painstomach or belly pain2.2%734
24. General physical health deteriorationgeneral decline in health2.2%716
25. Thrombotic microangiopathy2%678
26. Acute kidney injurysudden loss of kidney function2%673
27. Decreased appetitereduced appetite1.9%629
28. Platelet count decreasedlow platelet count1.8%602
29. Neoplasm progression1.7%575
30. Pulmonary embolisma blood clot in the lung1.7%573

Top 30 of 2,319 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 19 drugs in the nucleoside metabolic inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 313,386 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 26% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 33,198 reports.

Drugs most often listed in the same reports

Other products listed in reports where Gemcitabine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the nucleoside metabolic inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Gemcitabine as a suspect or interacting product; reports listing it only as a concomitant medication (6,342) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.